Related Experiment Video
Updated: Jul 21, 2026
Step-specific Sorting of Mouse Spermatids by Flow Cytometry
Published on: December 31, 2015
Proteomic analysis of cisplatin-induced spermatogenesis defects in mice
Pengyu Li1,2, Ziran Chen2, Zexuan Zhang2
1Department of Rheumatology and Immunology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia Key Laboratory for Pathogenesis and Immunodiagnosis of Rheumatic and Immunological Diseases, Hohhot, China.
Background:
Cisplatin is a crucial chemotherapeutic agent used for treating various cancers; however, its excessive use can cause irreversible damage to the reproductive system, and the protein expression profile of cisplatin-induced testicular injury remains unclear.
Methods:
Male C57BL/6 mice were treated with cisplatin at various doses, and testes were collected for histological, immunofluorescence, and proteomic analyses. Germ cell loss and apoptosis were assessed using H&E staining, TUNEL assays, and immunofluorescence for LIN28A, SYCP3, MVH, and CDK1. Label-free quantitative proteomics identified differentially expressed proteins, which were analyzed for functional enrichment and protein-protein interactions.
Results:
We observed that cisplatin treatment led to smaller testes, reduced sperm count, and a significant decrease in the number of spermatocytes and spermatids in mice. Label-free quantitative proteomic analysis revealed that cisplatin significantly reduced the expression of cyclin-dependent kinase 1 (CDK1), a key spermatogenesis regulator, in the testes. Reduction in CDK1 expression is correlated with spermatogenic arrest, particularly in spermatocytes.
Conclusion:
These findings highlight the critical role of CDK1 in cisplatin-induced spermatogenic dysfunction and provide new insights into fertility preservation strategies for patients with cancer undergoing chemotherapy.
Insights
Cisplatin chemotherapy damages male fertility by reducing sperm count and affecting germ cells. This study reveals that cisplatin lowers the expression of cyclin-dependent kinase 1 (CDK1), a key regulator of spermatogenesis, leading to reproductive dysfunction.
Area of Science:
- Reproductive biology
- Oncology
- Proteomics
Background:
- Cisplatin is a vital chemotherapy drug for various cancers.
- However, cisplatin can cause irreversible damage to the male reproductive system.
- The specific protein changes in cisplatin-induced testicular injury are not well understood.
Purpose of the Study:
- To investigate the effects of cisplatin on testicular tissue.
- To identify key proteins involved in cisplatin-induced testicular injury.
- To understand the role of these proteins in spermatogenesis.
Main Methods:
- Mice were treated with varying doses of cisplatin.
- Testes underwent histological, immunofluorescence, and proteomic analyses.
- Germ cell loss and apoptosis were quantified, and protein expression was analyzed.
Main Results:
- Cisplatin treatment resulted in smaller testes, reduced sperm count, and fewer spermatocytes and spermatids.
- Proteomic analysis showed significantly reduced expression of cyclin-dependent kinase 1 (CDK1).
- Lower CDK1 levels correlated with spermatogenic arrest, especially in spermatocytes.
Conclusions:
- CDK1 plays a critical role in cisplatin-induced testicular dysfunction.
- These findings offer insights into fertility preservation for cancer patients undergoing chemotherapy.
More Related Videos
09:40A Seminiferous Tubule Squash Technique for the Cytological Analysis of Spermatogenesis Using the Mouse Model
Published on: February 6, 2018
09:41Functional Assessment of Kinesin-7 CENP-E in Spermatocytes Using In Vivo Inhibition, Immunofluorescence and Flow Cytometry
Published on: December 28, 2021
Related Concept Videos
01:41Spermatogenesis
01:38Fertilization